Plasma fibrinogen plays a central role in hemostasis, serving as a precursor to fibrin and contributing to platelet aggregation and clot stability. As a result, plasma fibrinogen concentration has emerged as a clinically meaningful biomarker for assessing bleeding risk across a variety of surgical, traumatic, and medical settings. A substantial body of literature describes the relationship between hypofibrinogenemia and coagulopathy, supporting its use as an early and reliable indicator of hemorrhagic potential. Understanding this relationship is essential for guiding transfusion strategies, predicting clinical outcomes, and optimizing perioperative management.
Multiple studies demonstrate that low fibrinogen levels correlate strongly with increased bleeding severity, particularly in trauma and major surgical populations. In the setting of acute hemorrhage, fibrinogen is typically the first coagulation factor to fall to critically low levels, making it a sensitive marker of early coagulopathy. Research in both trauma and obstetric hemorrhage has shown that fibrinogen concentrations below 150–200 mg/dL are associated with significantly higher transfusion requirements, greater hemostatic instability, and increased mortality. These findings have contributed to the growing emphasis on rapid fibrinogen replacement through cryoprecipitate or fibrinogen concentrate during massive transfusion.
The predictive value of plasma fibrinogen for bleeding risk extends to the perioperative environment as well. Cardiac, hepatic, and orthopedic surgical literature consistently demonstrates that low preoperative or intraoperative fibrinogen levels are associated with higher postoperative bleeding rates and increased need for blood products. Patients undergoing cardiopulmonary bypass, for example, frequently experience hemodilution and fibrinogen depletion, and fibrinogen levels have been shown to predict chest tube output and re-exploration rates. Similarly, in liver transplantation and major hepatic resections, where coagulopathy is common, fibrinogen serves as a practical marker of both synthetic capacity and bleeding risk.
In obstetrics, fibrinogen has been particularly valuable as a prognostic tool. Studies examining postpartum hemorrhage reveal that fibrinogen levels decline early in the course of severe bleeding and that a level below 200 mg/dL strongly predicts progression to massive hemorrhage. Because pregnancy typically elevates fibrinogen levels as part of a procoagulant physiological shift, a “normal” laboratory value may still represent a pathological decline in the obstetric population. As such, plasma fibrinogen has become integral in early risk stratification and intervention algorithms for postpartum hemorrhage.
Beyond acute care settings, fibrinogen levels have diagnostic relevance in chronic disease states as well. Patients with congenital hypofibrinogenemia or dysfibrinogenemia exhibit variable bleeding risk depending on functional activity and antigenic levels. In oncologic or inflammatory conditions, fibrinogen levels may rise as an acute-phase reactant, sometimes complicating interpretation but still offering insight into hemostatic balance when evaluated in appropriate clinical context.
Despite its utility as a predictor of bleeding risk, fibrinogen measurement is not without limitations. Standard laboratory assays may not capture real-time changes during active bleeding, prompting use of viscoelastic testing (such as ROTEM or TEG) for faster assessment. Furthermore, fibrinogen levels should be evaluated alongside platelet count, coagulation studies, and clinical presentation to produce a comprehensive bleeding risk assessment. No single laboratory value can fully predict hemorrhage, but fibrinogen offers one of the most reliable biochemical indicators available.
Overall, plasma fibrinogen has solidified its place as a clinically meaningful predictor of bleeding risk. Its early depletion in massive hemorrhage, consistent correlation with transfusion requirements, and prognostic value across trauma, surgery, and obstetrics underscore its importance in modern hemostatic management. As testing becomes more rapid and replacement therapies more accessible, fibrinogen measurement is likely to play an increasingly central role in both prevention and treatment of bleeding complications.
References
- Levy JH, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion. 2015;55(2):298-304. DOI: 10.1111/trf.12431
- Hiippala ST. Fibrinogen and massive bleeding: identification and management. Semin Thromb Hemost. 2000;26(1):67-72. DOI: 10.3390/jcm10173930
- Rourke C, Curry N, Khan S, et al. Fibrinogen levels as a predictor of bleeding in trauma patients: an observational study. Crit Care. 2012;16(4):R137. DOI: 10.1016/j.injury.2017.01.031
- Karlsson M, Ternström L, Hyllner M, et al. Plasma fibrinogen as a predictor of postoperative bleeding after cardiac surgery. Eur J Cardiothorac Surg. 2009;36(4):698-703. DOI: 10.1532/HSF98.20071065
Recent Comments